Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NeoGenomics Inc. Common Stock (NEO) vs NOV Inc. Common Stock (NOV) Price & Performance

NeoGenomics Inc. Common StockTrade
NOV Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

NeoGenomics Inc. Common Stock vs NOV Inc. Common Stock — how do they compare? NeoGenomics Inc. Common Stock trades at $17 (market cap $2.17B), while NOV Inc. Common Stock trades at $18.75 (market cap $6.68B). The key difference: NOV Inc. Common Stock is far larger — about 3.1× NeoGenomics Inc. Common Stock's market cap, and NOV Inc. Common Stock pays a 1.92% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and NOV Inc. Common Stock for 6 Days on average.

NEONOV
Market Cap
$2.17B$6.68B
Volume
1,615,9434,702,090
Sector
HealthEnergy
52-Week High
$19.91$21.71
52-Week Low
$7.19$12.66
Typical Hold Time
0 Days6 Days
Enterprise Value
$2.47B$7.85B
Dividend Yield
—1.92%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NeoGenomics Inc. Common Stock

No Aura AI signal available yet.

NOV Inc. Common Stock

NOV trades at $18.96, up 0.37% with a bearish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates but showing revenue decline. Valuation metrics show a high P/E ratio of 70.22 but attractive P/S of 0.81, while profitability remains weak with 1.1% net margin. Recent news highlights strong subsea demand but Middle East risks and weak equipment sales.

The outlook is cautious with analyst consensus at $21.80 target (15% upside) but technical weakness. Investment opportunity lies in energy equipment strength and margin improvements, while risks include geopolitical exposure, competitive pressures, and inconsistent earnings performance. The stock faces headwinds from capital spending constraints in the oilfield sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NEO
100% Buy0% Sell
Avg holding period · 0 Days
NOV

No sentiment data available yet.

About NeoGenomics Inc. Common Stock

NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.

Read more on NEO →

About NOV Inc. Common Stock

NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.

Read more on NOV →